Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
Charles M. Rudin, Gini F. Fleming, Sridhar Mani, Walter M. Stadler, Philip Schumm, Mark J. Ratain, Jon Holmlund, Brett P. Monia, Joseph F. Johnston, Richard Geary, Rosie Z. Yu, T. Jesse Kwoh, F. Andrew Dorr
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer'. Together they form a unique fingerprint.